ReviewGenetically engineered murine models – Contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma
Introduction
Recent advances in genetically engineered mouse modeling (GEMM) technology have provided unique opportunities to address fundamental questions about the developmental origin, molecular pathology and therapeutic susceptibility of pediatric cancers. As expertise grows in understanding of neural crest development and specification, and in the function of oncogenic drivers of the childhood cancer neuroblastoma, GEMM approaches will provide the means to validate these drivers and to generate important future models. This article reviews current models and GEMM strategies aimed at elucidating genes that alter neural crest fate specification and neuroblast function, and that thereby contribute to the formation of NB tumors.
In general, GEMM are most commonly developed to provide mechanistic data elucidating causal roles for particular genes in developmental fate specification or oncogenesis. Developmentally focused approaches examine whether an observed phenotype is associated with tissue- and/or time-specific mis-expression of a gene that regulates differentiation program of the target tissues. For this reason, targeted knock-in strategies incorporating some form of imaging, and the ability to regulate expression of the gene of interest, are most commonly used. The ability to control expression of the target gene in a time-dependent manner and to visualize expression are equally critical to the elucidation of molecular oncogenic mechanisms and to efforts to develop novel therapeutics, respectively.
Cancer focused GEMM strategies seek to determine more specifically: (1) whether altered expression of a cancer-associated gene or mutation can initiate and sustain tumorigenesis, (2) what clinical phenotype if any, is recapitulated by the model, (3) whether the oncoprotein target itself or changes in molecular signaling pathways induced by its mis-expression represent therapeutic targets, and (4) whether secondary genomic alterations evolve and are required for oncogenesis, and 5, whether these validated genes also be therapeutic targets. In neuroblastoma in particular, the sequence of genetic events underlying normal maturation of neural crest precursors is now understood in some detail. Manipulated expression of such genes (PHOX2B, Sox10, Hand2, and TH) promises to provide great insights into where these initiating defects occur, and how they impact the ultimate biology of neural crest-derived malignancy.
Given that many, if not most, pediatric (embryonal) cancers represent aberrations of normal developmental programs, GEMM approaches are ideal in that they combine elements of both controlled and visualized expression. In pediatric cancer the question of whether a particular gene is oncogenic often relates to its role in development, and this by nature demands the ability to manipulate gene expression, ideally in a fully reversible manner, and requires the capacity to confirm gene expression using a surrogate marker. Additional imaging techniques that serve as rapid and practical screens for presence of tumor, and are capable of quantitating volume or bulk responses in the setting of a pre-clinical drug trial are equally critical. Appropriate credentialing of a murine model for therapeutic use is vital and challenging. Below, we review some of the technologies and approaches available in these areas.
Section snippets
How murine genetic models could contribute to a complete understanding of NB
Major differences exist between pediatric and adult cancers in the genesis of the most common non-germline cancers. Spontaneous adult malignancies largely result from stochastic accumulation of somatic genetic mutations and epigenetic changes over a relatively long timescale [1], [2], [3]. In contrast, transformation in many pediatric cancers is initiated by comparably few “driver” mutations that occur during a short window of programmed differentiation [4]. Clones that acquire a survival
Existing GEMM models of NB–TH-MYCN
The crucial role of MYC genes in development of the central and peripheral nervous systems and their derived cancers has been recognized since the identification of MYC and MYCN as cellular homologues of v-MYC (avian myelocytomatosis inducing virus derived oncogene) [5], [6], [7], [8], [9], [10]. Initial attempts using mice to model the role of MYC genes in specification of brain and neural crest derived structures used targeted knock-in approaches to ablate endogenous expression of MYC or
Modeling NB genetics – MYCN modifiers
One of the obvious strengths of GEMM is in the identification of genetic modifiers through forward genetic screens. Cellular expression of MYCN induces a potent oncogenic stimulus that requires significant remodeling of metabolism, cell cycle checkpoint function, apoptotic potential and DNA damage repair mechanisms [51], [52], [53]. A critical question for understanding the role of MYCN as a target is how overexpression of MYCN, and MYC genes in general, is tolerated by cells [54], [55], [56].
Modeling MYCN-targets and cooperating genes
Simple genetic intercrosses (Fig. 2) provide an additional, candidate-driven means to assess cooperativity between an oncogene and additional gene targets in the genesis of a particular tumor. This approach can also help to clarify the oncogenically relevant targets, which in the case of MYC is particularly useful since the gene-set regulated by this enigmatic family of transcription factors encompasses thousands of targets regulating ribosomal and protein biosynthesis, metabolism and
Modeling the role of p53 pathway
Trp53 is important in NB, since MYC-driven cancers are characterized by coordinate induction of proliferation and apoptosis, with both ARF and p53 pathways implicated [68], [83], [84], [85], [86]. Concurrent deletion of p53 enhances tumorigenesis by MYC in a wide range of tumor models [87], [88]. The advent of GEMM with reactivatable p53 transgenes has provided an additional opportunity to study the impact of p53 modulation in the context of MYCN misexpression. Mutations in p53 occur commonly
Beyond MYCN modeling – ALK and PHOX2B
That relatively few mutations drive the majority of NB cases is clear from recent genome-wide studies. MYCN is a definitive marker of 40% of high-risk NB, however the majority of high-risk cases are not defined by known single gene alterations [89]. The recognition that distinct ALK mutations are differentially present within the germline and somatic tumor tissue of NB patients, and underlie the majority of hereditary NB, led to the elegant validation of Knudson's two-hit hypothesis (describing
Beyond MYCN modeling – additional targets
Since aberrant control of MYCN and ALK accounts for only a minority of high-risk patients, additional models are needed both for MYCN-independent high-risk disease, and for intermediate-risk patients. Genome-wide-association-studies are rapidly defining the spectrum of nucleotide polymorphisms, copy number variations, expression changes and epigenetic events that account for a predisposition to both sporadic and familial NB and which appear to selectively associate with discrete tumor
Modeling of additional expression and genomic alterations
Cross-platform, integrative genomic screens that analyze copy number abnormalities (CNAs) suggest that distinct patient populations are defined by global patterns that cluster alterations in DNA ploidy and focal-segmental copy number (numerical or focal segmental copy number changes) [118], [119], [120]. These include the commonly observed regions of focal gain and loss (1p36, 11q, 13, 14, gain of 17p), which are being incorporated into clinical risk-assignment systems. With the routine
Modeling NB as a deficiency of neural crest development
NB is one of several neurocristopathies associated with disordered development of the autonomic nervous system, including central hypoventilation syndrome, Hirschsprung disease, pheochromocytoma and neurofibromatosis [139]. The high degree of clinical diversity and specificity of age distribution reinforces the hypothesis that specific NB phenotypes are likely to originate from distinct aberrations that occur at specific points within the neural crest fate-specification pathway. The use of GEMM
Technologies for current and future modeling strategies
The TH-MYCN model utilized comparatively simple, non-targeted tissue-specific mis-expression (a conventional transgenic approach, to establish that targeted expression of an initiating oncogene could drive NB (Fig. 4A). Given the unique biology of this disease as a derivative of aberrant neural crest differentiation and its propensity to regress in an age- and time-dependent manner, future modeling strategies should incorporate technologies allowing for inducible or fully reversible expression
GEMM-based pre-clinical drug development
A potential strength of GEMM is their applicability to pre-clinical drug development, but efficient utilization for this purpose has not yet been fully realized. A significant deficiency of tumor implantation modeling has been lack of predictive power for clinical response, most likely related to altered behavior of implanted human cell lines in the subcutaneous murine microenvironment. It is becoming apparent that in certain trial designs, GEMM may provide superior modeling of drug response as
Conclusions
GEMM are continuing to define the role of clinically important mutations in the genesis of the major adult cancers. The use of GEMM-based approaches is increasing in pediatric cancer, and will play an important role in the development of novel therapeutics targeted at specific oncogenes and pathways. NB can be a paradigm for the rational development of GEMM that define all discrete clinical cohorts of this distinctive cancer.
Conflict of interest
None.
References (157)
- et al.
A rapid and scalable system for studying gene function in mice using conditional RNA interference
Cell
(2011) - et al.
MYCN promotes the expansion of Phox2B-positive neuronal progenitors to drive neuroblastoma development
Am J Pathol
(2009) - et al.
Mdm2 deficiency suppresses MYCN-Driven neuroblastoma tumorigenesis in vivo
Neoplasia
(2009) - et al.
DRR1 is expressed in the developing nervous system and downregulated during neuroblastoma carcinogenesis
Biochem Biophys Res Commun
(2010) - et al.
Cell lines from MYCN transgenic murine tumours reflect the molecular and biological characteristics of human neuroblastoma
Eur J Cancer
(2007) - et al.
The Myc oncoprotein as a therapeutic target for human cancer
Semin Cancer Biol
(2006) - et al.
Proteins of the Myc network: essential regulators of cell growth and differentiation
Adv Cancer Res
(1996) - et al.
The ups and downs of Myc biology
Curr Opin Genet Dev
(2010) - et al.
Myc: a weapon of mass destruction
Cell
(2004) - et al.
Modeling the therapeutic efficacy of p53 restoration in tumors
Cell
(2006)
Bmi-1 is essential for the tumorigenicity of neuroblastoma cells
Am J Pathol
Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma
Neoplasia
The p53 pathway and its inactivation in neuroblastoma
Cancer Lett
Germline PHOX2B mutation in hereditary neuroblastoma
Am J Hum Genet
Darwinian medicine: a case for cancer
Nat Rev Cancer
Exploring the genomes of cancer cells: progress and promise
Science
Oncogene-dependent tumor suppression: using the dark side of the force for cancer therapy
Cold Spring Harb Symp Quant Biol
Childhood tumors of the nervous system as disorders of normal development
Curr Opin Pediatr
Activation of a cellular onc gene by promoter insertion in ALV-induced lymphoid leukosis
Nature
Multiple arrangements of viral DNA and an activated host oncogene in bursal lymphomas
Nature
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour
Nature
Differential expression of myc family genes during murine development
Nature
N-myc and c-src genes are differentially regulated in PCC7 embryonal carcinoma cells undergoing neuronal differentiation
J Cell Physiol
Proto-oncogene c-myc is expressed in cerebellar neurons at different developmental stages
EMBO J
Embryonic lethality in mice homozygous for a targeted disruption of the N-myc gene
Gene Dev
Defects in heart and lung development in compound heterozygotes for two different targeted mutations at the N-myc locus
Development (Cambridge, England)
Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop
Gene Dev
N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation
Gene Dev
c- and N-myc regulate neural precursor cell fate, cell cycle, and metabolism to direct cerebellar development
Cerebellum
N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation
Gene Dev
Clusterin, a haploinsufficient tumor suppressor gene in neuroblastomas
J Natl Cancer Inst
MYCN regulates oncogenic MicroRNAs in neuroblastoma
Int J Cancer
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster
Nat Genet
Targeted expression of MYCN causes neuroblastoma in transgenic mice
Embo J
Establishment of a novel neuroblastoma mouse model
Int J Oncol
Molecular characterization of tumors from a transgenic mouse adrenal tumor model: comparison with human pheochromocytoma
Int J Oncol
A novel basal promoter element is required for expression of the rat tyrosine hydroxylase gene
J Neurosci
Preclinical models for neuroblastoma: establishing a baseline for treatment
PLoS ONE
Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma
Cancer Res
A simple PCR method for rapid genotype analysis of the TH-MYCN transgenic mouse
PLoS ONE
Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction
Neoplasia
ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma
Cancer Res
Malignant progression and blockade of angiogenesis in a murine transgenic model of neuroblastoma
Cancer Res
Mechanisms of embryonal tumor initiation: distinct roles for MycN expression and MYCN amplification
Proc Natl Acad Sci U S A
Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors
Cancer Res
Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target
Cancer Res
Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma
Cancer Res
Histological profile of tumours from MYCN transgenic mice
J Clin Pathol
Regions syntenic to human 17q are gained in mouse and rat neuroblastoma
Gene Chromosome Cancer
Effects of MYCN antisense oligonucleotide administration on tumorigenesis in a murine model of neuroblastoma
J Natl Cancer Inst
Cited by (44)
Palbociclib releases the latent differentiation capacity of neuroblastoma cells
2023, Developmental CellShort overview on metabolomics approach to study pathophysiology of oxidative stress in cancer
2018, Redox BiologyCitation Excerpt :The MYCN gene is amplified and overexpressed in a large proportion of high stage neuroblastoma patients and has been recognized as a key driver of tumorigenesis. TH-MYCN transgenic mice expressing human MYCN gene develop murine equivalent of neuroblastoma with all the main signatures of human disease [75]. An interesting in vivo study that examined neuroblastoma of TH-MYCN mice in three different stages of tumor development (pre-tumor, early tumor and advanced tumor) revealed high dependence of carcinogenesis on the GSH metabolism and activities.
Glutathione biosynthesis is upregulated at the initiation of MYCN-driven neuroblastoma tumorigenesis
2016, Molecular OncologyCitation Excerpt :In the normal embryo, MYCN expression is high in the early post-migratory neural crest where it regulates the early sympathoadrenal lineage but it is gradually down-regulated and is generally expressed at low levels through postnatal life (Zimmerman et al., 1986). The causal role of MYCN expression in neuroblastoma tumorigenesis is supported by the observation that sympathetic tissue-specific expression of the human MYCN gene in TH-MYCN transgenic mice causes a murine equivalent of neuroblastoma that recapitulates almost all of the features of the human disease (Chesler and Weiss, 2011; Weiss et al., 1997). Currently, direct MYCN-targeted agents have not been developed, but there has been recent pre-clinical success with indirect treatment approaches that inhibit MYCN by targeting its expression, protein stability or transcriptional activity (Brockmann et al., 2013; Carter et al., 2015; Chipumuro et al., 2014; Puissant et al., 2013).
Metastasis in neuroblastoma: the MYCN question
2023, Frontiers in Oncology